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A case of autoimmune urticaria accompanying autoimmune 
polyglandular syndrome type III associated with 
Hashimoto’s disease, type 1 diabetes mellitus, and vitiligo
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Abstract 
We present a case of autoimmune polyglandular syndrome type III (APS III) associated with Hashimoto’s disease, type 1 diabetes mellitus, 
vitiligo and autoimmune urticaria. This rare genetic disorder occurs with unknown frequency in the Polish population. It is characterised 
by endocrine tissue destruction resulting in the malfunction of multiple organs. 
Several cases of APS III associated with organ-specific autoimmune diseases such as coeliac disease, hypogonadism and myasthenia gravis, 
as well as organ-nonspecific or systemic autoimmune diseases such as sarcoidosis, Sjögren syndrome, and rheumatoid arthritis have been 
described. To the best of our knowledge, we here describe the first case of APS III associated with autoimmune thyroiditis, type 1 diabetes 
mellitus, vitiligo and autoimmune urticaria in an adult patient. (Endokrynol Pol 2014; 65 (4): 320–323)
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Streszczenie
W pracy przedstawiono przypadek autoimmunologicznego zespołu wielogruczołowego typu III współistniejącego z przewlekłą po-
krzywka autoimmunologiczną. Autoimmunologiczny zespół wielogruczołowy jest rzadko rozpoznawany, a częstość jego występowania 
w Polsce pozostaje nieznana. 
Opisano przypadki autoimmunologicznego zespołu wielogruczołowego typu III współistniejącego z innymi chorobami o podłożu 
autoimmunologicznym, takimi jak choroba trzewna, hypogonadyzm, miastenia gravis, jak również z sarkoidozą, zespołem Sjögrena 
i reumatoidalnym zapaleniem stawów. Nie opisywano jednak wcześniej przypadku współistnienia pokrzywki autoimmunologicznej 
z autoimmunologicznym zespołem wielogruczołowym typu III. (Endokrynol Pol 2014; 65 (4): 320–323)
Słowa kluczowe: autoimmunologiczny zespół wielogruczołowy typu III; cukrzyca typu 1; autoimmunologiczne zapalenie tarczycy; bielactwo; 
pokrzywka autoimmunologiczna 
Introduction
Polyglandular autoimmune syndromes (APSs) are 
a group of autoimmune disorders characterised by 
endocrine tissue destruction causing malfunction of 
multiple glands [1]. The first classification of polyglan-
dular failure, distinguishing three types, was developed 
in 1980 by Neufeld and Blizzard [2]. APS I is character-
ised by candidiasis of the skin and mucous membranes, 
hypoparathyroidism and adrenal insufficiency. APS 
II is composed of adrenal insufficiency, autoimmune 
thyroid disease and type 1 diabetes mellitus (T1DM). 
APS III is a an adult type of APS, characterised by 
the association of endocrine and non-endocrine organ 
specific autoimmune disorders [1, 3]. Autoimmune 
thyroiditis and the absence of adrenal insufficiency 
are crucial for the diagnosis of all subtypes of APS III 
[1]. In APS III, autoimmune thyroiditis occurs together 
with another organ-specific autoimmune disease. APS 
III can be further divided into three subtypes: APS 
IIIA — autoimmune thyroiditis AITD with T1DM; 
APS IIIB — autoimmune thyroiditis with pernicious 
anaemia; and APS IIIC — autoimmune thyroiditis with 
vitiligo and/or alopecia and/or another organ-specific 
autoimmune disease. APS III may be accompanied 
by other organ-specific autoimmune diseases such as 
coeliac disease, hypogonadism, myasthenia gravis, 
autoimmune hepatitis as well as organ-nonspecific or 
systemic autoimmune diseases like sarcoidosis, Sjogren 
syndrome, rheumatoid arthritis, autoimmune leucope-
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nia and other diseases such as gastric carcinoid tumour, 
malabsorption due to exocrine pancreatic deficiency, 
idiopathic thrombocytopenic purpura or acquired von 
Willebrand syndrome [1, 3–6]. Amerio et al. considered 
chronic urticaria as an element of APS III C, however 
to the best of our knowledge, we here present the first 
case of APS III associated with autoimmune urticaria [7]. 
Case report
An obese 37-year-old woman was admitted to the De-
partment of Internal Diseases, Diabetology, and Clinical 
Pharmacology of the Medical University of Lodz due 
to weakness, sweating, dyspnoea, and tachycardia. 
The patient complained of menorrhagia. She had been 
diagnosed with type 1 diabetes mellitus at the age 
of 12. Since the diagnosis she had been treated with 
intensive insulin therapy, and the diabetes was rela-
tively well controlled. At the age of 30, her first vitiligo 
lesions appeared. Soon after, Hashimoto’s disease was 
diagnosed and treatment with L-thyroxin at a dose of 
50 µg/day was started. For several years, she was on 
antihypertensive medications. Additionally, she had 
suffered from depression since early adulthood. Several 
months before the first hospitalisation in our clinic, she 
was hospitalised due to stroke with paralysis of the left 
side. Computerised tomography revealed malformation 
of brain arteries, but the patient did not agree to any fur-
ther diagnostic or therapeutic procedures. The patient 
had no family history of APS or autoimmune thyroid 
disease (AITD) or any other immunological disorders. 
The physical examination on admission showed 
a markedly obese (BMI 38 kg/m2) woman with visible 
oedema of the face and extremities. The patient pre-
sented with a generalised form of vitiligo. Numerous 
amelanotic patches were present on the hands, fore-
arms, feet, face and trunk. Neurological examination 
revealed the signs of distal symmetric polyneuropathy. 
Signs of hypertonic as well as diabetic retinopathy were 
seen on ophthalmoscopic examination. ECG tracings 
showed sinus rhythm 80/min with single supraventricu-
lar extrasystoles, and negative T wave in V1-V3 leads. 
Abdominal ultrasound, as well as chest X-ray, were 
normal. Thyroid ultrasound revealed small thyroid 
gland, typically located, without any focal abnormali-
ties. Results of laboratory tests are presented in Table I. 
Based on the obtained results, APS III and L-thyroxin 
overdosing were diagnosed. The dose of L-thyroxin was 
reduced by 50% and the patient’s condition improved 
two weeks after discharge.
The patient was admitted again to our clinic two 
years after the first admission due to generalised wheals, 
redness and itching of the face, trunk and extremities. 
The skin lesions had appeared several weeks before the 
hospitalisation. In outpatient settings, she was treated with 
clemastine (1 mg bid, with a further increase in the dose 
to 2 mg bid). The clemastine was withdrawn due to side 
effects, and deslorataine (10 mg qd) was administered. 
Additionally, she was given predisone (60 mg/day, with 
a further reduction in the dose). Despite treatment with 
high doses of H1 antihistamine medications and oral cor-
ticosteroids, the skin lesions were resistant to treatment. 
During hospitalisation, a differential diagnosis 
aimed at parasitic infection, Helicobacter pylori infection, 
allergic contact dermatitis, drug eruptions, neoplasia, 
Table I. Results of basic laboratory tests and diagnostic tests 
aimed at diagnosis of autoimmune diseases at first admission
Tabela I. Wyniki podstawowych badań laboratoryjnych 
i badań diagnostycznych mających na celu diagnozowanie 
chorób autoimmunologicznych podczas pierwszego przyjęcia
Parameter Result
Leukocyte count [103/µL] 11.12/9.27
Erythrocyte count [106/µL] 4.44/4.67
Haemoglobin [g/dL] 10.5/10.9
Hematocrit (%) 30.9/33.0
Platelet count [103/µL] 246/303
Iron [µmol/L] 7.05
Total Iron Binding Capacity (TIBC) [mmol/L] 69.9
Unsaturated Iron Binding Capacity (UIBC) [mmol/L] 62.8
Ferritine [ng/mL] 7.57
Alanine aminotransferase (ALT) [U/L] 27
Aspartate aminotransferase (AST) [U/L] 26
Bilirubin [µmol/L] 9.8
Creatinine [µmol/L] 58
Urea [mmol/L] 3.9
Sodium [mmol/L] 138
Potassium [mmol/L] 4.6
Glycated haemoglobin (%) 9.24
Total cholesterol [mmol/L] 5.7
LDL cholesterol [mmol/L] 3.7
HDL cholesterol [mmol/L] 1.11
Triglycerides [mmol/L] 1.78
Thyrotropin (TSH) [µIU/mL] 6.01
Free triiodothyronine (fT3) [pmol/L] 4.76
Anti-thyroid peroxidase antibody
Anti-TPO (normal range < 40 UI/mL)
5,917.8
Anti-thyroglobulin antibody 
Anti-Tg (normal range < 40 UI/mL)
366.17
Anti-thyrotropin receptor antibody TSHR  
(normal range < 1.5 UI/mL)
13.23
Cortisol (normal range 5–25 µg/dL) 12.9
Adrenocorticotropic hormone (normal range 10–80 ng/L) 16.4
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lymphoedema, dermatomyositis, erythema multiforme, 
and Crohn’s disease was performed, and these condi-
tions were excluded. Additionally, the presence of 
potential foci of inflammation was also excluded. 
The suspicion of autoimmune urticaria was made 
and the patient was consulted in the Clinic of Dermatol-
ogy and Venerology of the Medical University of Lodz. 
Implementation of an autologous serum skin test and 
a skin biopsy were advised, but the patient did not agree 
to skin biopsy. The results of the autologous serum 
skin test [8] were positive and a diagnosis of autoim-
mune urticaria associated with APS III syndrome was 
made. Oral corticosteroids were initially increased. The 
patient was highly intolerant to corticosteroids due to 
substantial weight gain and deregulation of glucose me-
tabolism, and the therapy was withdrawn. Small doses 
of azathioprine (25 mg qd) were introduced, and the 
skin lesions disappeared completely within two weeks. 
After several weeks, the generalised wheals, redness 
and itching reappeared despite immunosuppressive 
treatment. The doses of azathioprine were increased, 
but the efficacy was moderate. The patient herself de-
cided to withdraw immunosuppressive therapy and 
independently started on a low calorie diet. She was 
highly motivated and managed to lose 20 kilograms in 
six months. Symptoms of urticaria subsided gradually 
with time and disappeared completely within a few 
months with no treatment. This observation is in agree-
ment with the results of the study of Ye et al., who noted 
that in a Korean population, the presence of metabolic 
syndrome was an independent predictor of uncon-
trolled chronic urticaria [9]. Weight loss also resulted in 
a substantial improvement of glucose homeostasis and 
diminishment of symptoms of depression. 
Discussion
There are several hypotheses explaining the develop-
ment of different components of APS III [1, 10–16]. 
The most widely accepted is the autoimmune genetic 
hypothesis, assuming involvement of genes associated 
with immune regulation [17]. Numerous observations 
have confirmed that genetic susceptibility is shared 
among autoimmune diseases, with the strongest asso-
ciation seen between T1DM and autoimmune thyroid 
disease (AITD) [11, 12, 18–21]. 
The prevalence of APS III in different populations 
including the Polish population is not known. APS III 
can occur in persons of any age, although it is most 
common in middle aged women. The clinical symp-
toms of individual components of APS III are identical 
to those of the insufficiency of the individual gland(s). 
Various skin pathologies related to numerous endocrine 
disorders, including diabetes mellitus and autoimmune 
thyroid disease, are relatively common. However, to 
the best of our knowledge, autoimmune urticaria ac-
companying APS III syndrome in an adult patient has 
never been described before. 
Chronic urticaria may be associated with autoim-
mune thyroiditis and antithyroid antibodies [13]. It is 
supposed to be caused by IgG antibody to the a subunit 
of the IgE receptor. It seems that activation of comple-
ment is associated with augmented histamine secretion 
by release of C5a [24]. The incidence of anti-thyroid 
antibodies in chronic urticaria varies between 15% and 
24% [25, 26]. Grattan et al. examined antibodies reactive 
with skin mast cells by performing an autologous skin 
test. The reaction was positive in 30% of patients with 
chronic urticaria [27, 28]. In healthy control subjects, or 
patients with other forms of urticaria, positive reactions 
were rare. Histological examination in patients with 
chronic autoimmune urticaria reveals a perivascular 
infiltrate with CD4+ lymphocytes as well as monocytes, 
neutrophils, eosinophils, and basophils [24]. As seen in 
our patient, in the most severe cases of autoimmune 
urticaria, patients may require treatment with immu-
nosuppressive agent(s). 
It is of interest that the symptoms of autoimmune 
urticaria in the patient subsided gradually with weight 
loss without any treatment of urticaria. Weight reduc-
tion was associated with a substantial improvement in 
the patient’s mood. 
In order to unify the obesity with different components 
of APS III, it is necessary to identify common patho-
physiological mechanisms responsible for the metabolic 
abnormalities at many different levels [29]. Adipose tissue 
is a hormonally active organ synthesising and secreting a 
number of very active biomolecules, including adipokines 
[30–33]. Adipokines are involved in regulating numerous 
physiologic and pathologic processes through signalling 
to different organs including the brain, liver and skeletal 
muscle. Adipokines are also involved in maintaining ho-
meostasis of the immune system, blood pressure, glucose 
and lipid metabolism as well as pathological processes 
such as inflammation and atherosclerosis. We did not 
assess levels of individual adipokines, however one can 
speculate that weight loss in the described patient had 
a beneficial impact on the biological activity of adipose 
tissue. As a consequence, production and secretion of pro-
inflammatory cytokines could be reduced, leading to the 
diminution of intensity of symptoms of urticaria over time. 
Conclusions
Autoimmune urticaria may be associated with autoim-
mune polyglandular syndrome type III and obesity. It 
seems that weight reduction could diminish the signs 
and symptoms of urticaria. 
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The patient’s written consent to the publication of 
all medical data was obtained prior to submitting this 
article.
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